JPWO2020249528A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020249528A5
JPWO2020249528A5 JP2021573165A JP2021573165A JPWO2020249528A5 JP WO2020249528 A5 JPWO2020249528 A5 JP WO2020249528A5 JP 2021573165 A JP2021573165 A JP 2021573165A JP 2021573165 A JP2021573165 A JP 2021573165A JP WO2020249528 A5 JPWO2020249528 A5 JP WO2020249528A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutical composition
adc
individual
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021573165A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535609A (ja
Publication date
Priority claimed from GBGB1908234.6A external-priority patent/GB201908234D0/en
Priority claimed from GBGB1908233.8A external-priority patent/GB201908233D0/en
Application filed filed Critical
Priority claimed from PCT/EP2020/065880 external-priority patent/WO2020249528A1/en
Publication of JP2022535609A publication Critical patent/JP2022535609A/ja
Publication of JPWO2020249528A5 publication Critical patent/JPWO2020249528A5/ja
Pending legal-status Critical Current

Links

JP2021573165A 2019-06-10 2020-06-08 抗ｃｄ１９抗体薬物複合体とｐｉ３ｋ阻害剤又は二次薬剤を含む併用治療 Pending JP2022535609A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1908234.6A GB201908234D0 (en) 2019-06-10 2019-06-10 Combination therapy
GBGB1908233.8A GB201908233D0 (en) 2019-06-10 2019-06-10 Combination therapy
GB1908234.6 2019-06-10
GB1908233.8 2019-06-10
PCT/EP2020/065880 WO2020249528A1 (en) 2019-06-10 2020-06-08 Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent

Publications (2)

Publication Number Publication Date
JP2022535609A JP2022535609A (ja) 2022-08-09
JPWO2020249528A5 true JPWO2020249528A5 (ko) 2023-06-13

Family

ID=71103360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573165A Pending JP2022535609A (ja) 2019-06-10 2020-06-08 抗ｃｄ１９抗体薬物複合体とｐｉ３ｋ阻害剤又は二次薬剤を含む併用治療

Country Status (11)

Country Link
US (1) US20220305132A1 (ko)
EP (1) EP3980079A1 (ko)
JP (1) JP2022535609A (ko)
KR (1) KR20220020332A (ko)
CN (1) CN114302745A (ko)
AU (1) AU2020292965A1 (ko)
CA (1) CA3142645A1 (ko)
IL (1) IL288716A (ko)
MX (1) MX2021015403A (ko)
SG (1) SG11202113092WA (ko)
WO (1) WO2020249528A1 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022262606A1 (en) 2021-04-21 2023-11-09 Indapta Therapeutics, Inc. Methods of treatment and dosing of natural killer cell compositions
WO2024028433A1 (en) * 2022-08-04 2024-02-08 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of lymphoproliferative disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
EP2550975A1 (en) * 2011-07-29 2013-01-30 Sanofi Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab
NZ707490A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
NZ707534A (en) 2012-10-12 2018-08-31 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201506399D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
WO2017160954A1 (en) * 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
CA3057749A1 (en) * 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy
BR112019026564A2 (pt) * 2017-06-14 2020-06-30 Adc Therapeutics Sa regimes de dosagem para a administração de um adc anti-cd19
CA3107085A1 (en) * 2018-08-31 2020-03-05 Adc Therapeutics Sa Combination of anti-cd19 antibody-pyrroloenzodiazepine conjugate and ve netoclax
WO2020109251A1 (en) * 2018-11-29 2020-06-04 Adc Therapeutics Sa Dosage regime

Similar Documents

Publication Publication Date Title
JP2022017295A5 (ko)
JP2018524347A5 (ko)
HRP20171727T1 (hr) Novi terapeutici
JP2019506403A5 (ko)
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
JP2020505433A5 (ko)
JP2019510832A5 (ko)
RU2019138222A (ru) Применение ингибитора ezh2 в комбинации с ингибитором btk в получении лекарственного средства для лечения опухоли
JP2020506951A5 (ko)
JP2009536620A5 (ko)
JP2008530142A5 (ko)
KR20080004495A (ko) 암을 치료하기 위한 조합물, 방법 및 조성물
JP6184952B2 (ja) 抗ｃｄ１９抗体とナイトロゲンマスタードとの併用療法
JP2019517485A5 (ko)
JP2018503610A5 (ko)
JP2014511383A5 (ko)
JP2020531414A5 (ko)
US9119877B2 (en) Therapeutic combination comprising a Cdc7 inhibitor and an anti-neoplastic agent
JP2022137089A (ja) 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用
AU2012296907A1 (en) Combination therapy with an anti - CD19 antibody and a nitrogen mustard
JP2022508935A (ja) がん治療における免疫モジュレーションのための組合せ
TW202327569A (zh) 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途
EP2144630A2 (en) Chk1 inhibitors with b cell depleting antibodies for the treatment of hematologic malignancies
JPWO2020249528A5 (ko)
JP2005535608A (ja) エポシロンを含む組み合わせおよびその薬学的使用